Advertisement
Screener

Seres Therapeutics, Inc. (MCRB) Stock Issued During Period, Value, Employee Stock Purchase Plan

2.8 / 5 stars · 68/120 Roast Me

Seres Therapeutics, Inc. Stock Issued During Period, Value, Employee Stock Purchase Plan

New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.

  • Seres Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2026-03-31 was $28.00K, a 84.78% decline year-over-year.
  • Seres Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-09-30 was $46.00K, a 65.67% decline year-over-year.
  • Seres Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-03-31 was $184.00K, a 47.88% decline year-over-year.
  • Seres Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2024-09-30 was $134.00K, a 85.47% decline year-over-year.
  • Seres Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2025 was $230.00K, a 52.77% decline from fiscal 2024.
  • Seres Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2024 was $487.00K, a 77.36% decline from fiscal 2023.
  • Seres Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2023 was $2.15M, a 21.59% increase from fiscal 2022.
  • Seres Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2022 was $1.77M, a 113.91% increase from fiscal 2021.
Period endStock Issued During Period, Value, Employee Stock Purchase Plan 3 monthStock Issued During Period, Value, Employee Stock Purchase Plan 12 month
2026-03-31$28.00K
10-Q · filed 2026-08-05
2025-12-31$230.00K
10-K · filed 2026-03-12
2025-09-30$46.00K
10-Q · filed 2025-11-05
2025-03-31$184.00K
10-Q · filed 2026-08-05
2024-12-31$487.00K
10-K · filed 2026-03-12
2024-09-30$134.00K
10-Q · filed 2025-11-05
2024-03-31$353.00K
10-Q · filed 2025-11-05
2023-12-31$2.15M
10-K · filed 2026-03-12
2023-09-30$922.00K
10-Q · filed 2024-11-13
2023-03-31$1.23M
10-Q · filed 2024-11-13
2022-12-31$1.77M
10-K · filed 2025-03-13
2022-09-30$877.00K
10-Q · filed 2023-11-02
2022-03-31$892.00K
10-Q · filed 2023-11-02
2021-12-31$827.00K
10-K · filed 2024-03-05
2021-09-30$435.00K
10-Q · filed 2022-11-02
2021-03-31$392.00K
10-Q · filed 2022-11-02
2020-12-31$462.00K
10-K · filed 2023-03-07
2020-09-30$213.00K
10-Q · filed 2021-11-10
2020-03-31$249.00K
10-Q · filed 2021-11-10
2019-12-31$296.00K
10-K · filed 2022-03-01
2019-09-30$89.00K
10-Q · filed 2020-11-09
2019-03-31$207.00K
10-Q · filed 2020-11-09
2018-12-31$257.00K
10-K · filed 2021-03-02
2018-09-30$257.00K
10-Q · filed 2019-11-05

Similar stocks

Stock NameCountryMarket CapPE Ratio
MIRA PHARMACEUTICALS, INC. (MIRA)United States$0.036B-4.30
BriaCell Therapeutics Corp. (BCTX)$0.037B
PMGC Holdings Inc. (ELAB)United States$0.037B
FILANA THERAPEUTICS, INC. (FLNA)United States$0.038B-1.05
Actinium Pharmaceuticals, Inc. (ATNM)United States$0.038B2.73
ROCKWELL MEDICAL, INC. (RMTI)United States$0.035B
Celularity Inc (CELU)United States$0.038B-0.34
CervoMed Inc. (CRVO)United States$0.038B-1.39
Context Therapeutics Inc. (CNTX)United States$0.034B-1.10
Edesa Biotech, Inc. (EDSA)Canada$0.039B